Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients

References

• KesslerRCDuPontRLBerglundPWittchenHUImpairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveysAm J Psychiatry1999156121915192310588405
   PubMed Web of Science ®Google Scholar
• BallengerJCDavidsonJRLecrubierYConsensus statement on generalized anxiety disorder from the International Consensus Group on Depression and AnxietyJ Clin Psychiatry200162Suppl 11535811414552
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text RevisionWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• WittchenHUGeneralized anxiety disorder: prevalence, burden, and cost to societyDepress Anxiety200216416217112497648
   PubMed Web of Science ®Google Scholar
• GrantBFHasinDSStinsonFSPrevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related ConditionsPsychol Med200535121747175916202187
   PubMed Web of Science ®Google Scholar
• WittchenHUJacobiFRehmJThe size and burden of mental disorders and other disorders of the brain in Europe 2010Eur Neuropsychopharmacol201121965567921896369
   PubMed Web of Science ®Google Scholar
• HuntCIssakidisCAndrewsGDSM-IV generalized anxiety disorder in the Australian National Survey of Mental Health and Well-BeingPsychol Med200232464965912102379
   PubMed Web of Science ®Google Scholar
• PhillipsMRZhangJShiQPrevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–2005: an epidemiological surveyLancet200937396802041205319524780
   PubMed Web of Science ®Google Scholar
• MaXXiangYTCaiZJGeneralized anxiety disorder in China: prevalence, sociodemographic correlates, comorbidity, and suicide attemptsPerspect Psychiatr Care200945211912719366422
   PubMed Web of Science ®Google Scholar
• LeeSTsangAZhangMYLifetime prevalence and inter-cohort variation in DSM-IV disorders in metropolitan ChinaPsychol Med2007371617117038208
   PubMed Web of Science ®Google Scholar
• SunXLLiKQCuiLJEpidemiological survey on generalized anxiety disorder in 4 areas of Hebei provinceJ Clin Rehabil Tissue Eng Res2007113978427844
   Google Scholar
• LeeSTsangAChuiHKwokKCheungEA community epidemiological survey of generalized anxiety disorder in Hong KongCommunity Ment Health J200743430531917333348
   PubMed Web of Science ®Google Scholar
• LeeSMaYLTsangAKwokKGeneralized anxiety disorder with and without excessive worry in Hong KongDepress Anxiety2009261095696119496076
   PubMed Web of Science ®Google Scholar
• HeYLMaHZhangLLiuZNJiaFJZhangMYA cross-sectional survey of the prevalence of depressive-anxiety disorders among general hospital outpatients in five cities in ChinaZhonghua Nei Ke Za Zhi200948974875120079212
   PubMedGoogle Scholar
• YingDGJiangSYangHZhuSFrequency of generalized anxiety disorder in Chinese primary carePostgrad Med20101224323820675969
   PubMed Web of Science ®Google Scholar
• ChienICChouYJLinCHBihSHChouPPrevalence of psychiatric disorders among National Health Insurance enrollees in TaiwanPsychiatr Serv200455669169715175468
   PubMed Web of Science ®Google Scholar
• WittchenHUZhaoSKesslerRCEatonWWDSM-III-R generalized anxiety disorder in the National Comorbidity SurveyArch Gen Psychiatry19945153553648179459
   PubMed Web of Science ®Google Scholar
• LiebRBeckerEAltamuraCThe epidemiology of generalized anxiety disorder in EuropeEur Neuropsychopharmacol200515444545215951160
   PubMed Web of Science ®Google Scholar
• BandelowBZoharJHollanderEWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revisionWorld J Biol Psychiatry20089424831218949648
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health (UK)Generalized Anxiety Disorder in Adults: Management in Primary, Secondary and Community CareLeicester, UKBritish Psychological Society2011
   Google Scholar
• HackettDHaudiquetVSalinasEA method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorderEur Psychiatry200318418218712814852
   PubMed Web of Science ®Google Scholar
• ChessickCAAllenMHThaseMAzapirones for generalized anxiety disorderCochrane Database Syst Rev20063CD00611516856115
   PubMed Web of Science ®Google Scholar
• BoschenMJA meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorderCan J Psychiatry201156955856621959031
   PubMed Web of Science ®Google Scholar
• KapczinskiFLimaMSSouzaJSSchmittRAntidepressants for generalized anxiety disorderCochrane Database Syst Rev20032CD00359212804478
   PubMedGoogle Scholar
• LaLondeCDVan LieshoutRJTreating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysisJ Clin Psychopharmacol201131332633321508847
   PubMed Web of Science ®Google Scholar
• GuaianaGBarbuiCCiprianiAHydroxyzine for generalised anxiety disorderCochrane Database Syst Rev201012CD00681521154375
   PubMed Web of Science ®Google Scholar
• WuWWangGBallSDesaiahDAngQQDuloxetine versus placebo in the treatment of patients with generalized anxiety disorder in ChinaInt J Neuropsychopharmacol20111242032603268
   Google Scholar
• UzunovaVShelineYDavisJMIncrease in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fuvoxamineProc Natl Acad Sci USA1998956323932449501247
   PubMed Web of Science ®Google Scholar
• RasmussonAMPinnaGPaliwalPDecreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorderBiol Psychiatry200660770471316934764
   PubMed Web of Science ®Google Scholar
• PinnaGCostaEGuidottiAFluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptakePsychopharmacology (Berl)2006186336237216432684
   PubMed Web of Science ®Google Scholar
• PinnaGDongEMatsumotoKCostaEGuidottiAIn socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetineProc Natl Acad Sci USA200310042035204012571361
   PubMed Web of Science ®Google Scholar
• PinnaGCostaEGuidottiASSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptakeCurr Opin Pharmacol200991243019157982
   PubMed Web of Science ®Google Scholar
• LohoffFWAquinoTDNarasimhanSMultaniPKEtemadBRickelsKSerotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorderPharmacogenomics J2013131212622006095
   PubMed Web of Science ®Google Scholar
• PorcelliSFabbriCSerrettiAMeta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacyEur Neuropsychopharmacol201222423925822137564
   PubMed Web of Science ®Google Scholar
• SmitsKMSmitsLJSchoutenJSStelmaFFNelemansPPrinsMHInfluence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic reviewMol Psychiatry20049543344115037864
   PubMed Web of Science ®Google Scholar
• YouJSHuSYChenBZhangHGSerotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorderPsychiatr Genet200515171115722951
   PubMed Web of Science ®Google Scholar
• Roy-ByrnePPPereraPPittsCDChristiJAParoxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysisJ Clin Psychiatry200566101228123316259535
   PubMed Web of Science ®Google Scholar
• KuroseKSugiyamaESaitoYPopulation differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug developmentDrug Metab Pharmacokinet201227195422123129
   PubMed Web of Science ®Google Scholar
• YinSJNiYBWangSMWangXLouYQZhangGLDifferences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populationsJ Clin Pharm Ther201237336436921913948
   PubMed Web of Science ®Google Scholar
• BradfordLDCYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendantsPharmacogenomics20023222924311972444
   PubMed Web of Science ®Google Scholar
• LiuZQChengZNHuangSLEffect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjectsBr J Clin Pharmacol2001521969911453896
   PubMed Web of Science ®Google Scholar
• LiuZQShuYHuangSLWangLSHeNZhouHHEffects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomesActa Pharmacol Sin2001221859011730569
   PubMed Web of Science ®Google Scholar
• LiGComparative study of escitalopram and fluoxetine in treatment of generalized anxiety disorderChinese Modern Medicine And Drug201127912871289
   Google Scholar
• ShaoGYComparative study of escitalopram and fluoxetine in the treatment of general anxiety disorder (GAD)China Journal of Health Psychology2013213327328
   Google Scholar
• TangKYeQHChenZBClinical controlled observation on generalized anxiety disorder treated by duloxetine and fluoxetine tabletsMedical Journal of Chinese People’s Health20122416061
   Google Scholar
• KimTSPaeCUYoonSJComparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorderPsychiatry Clin Neurosci200660334735116732752
   PubMed Web of Science ®Google Scholar
• BoseAKorotzerAGommollCLiDRandomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorderDepress Anxiety2008251085486118050245
   PubMed Web of Science ®Google Scholar
• SunJZWangSJSunTXA comparative study of fluoxetine and diazepam in the treatment of generalized anxiety disorderSichuan Psychological Health2000134253254
   Google Scholar
• LiuXCChenYXShuRHA comparative study of fluoxetine and diazepam in the treatment of patients with generalized anxiety disorderChinese Journal of Behavioral Medical Science2004133282283
   Google Scholar
• PengLWuDTuJA comparative study of fluoxetine and alprazolam in the treatment of generalized anxiety disorderChina Modern Doctor201250317879
   Google Scholar
• HeQXiaoPXZhangGCZhangCHComparative and double-blinded study of doxepine and fluoxetine in treatment of generalized anxiety disorder in 64 patientsShandong Medicine and Drugs20014142728
   Google Scholar
• XuJXTanJWQuLMComparison of the effect of fluoxetine and amitriptyline in treating comorbid depression disorder and anxiety disorderChinese Journal of Clinical Rehabilitation200481528122814
   Google Scholar
• ChenZLHuJMEffect analysis of fluoxetine in treating 55 patients with generalized anxiety disorderChinese Journal of Ethnomedicine and Ethnopharmacy20101914169170
   Google Scholar
• NiuFRShenXHSunSTComparison of efficacy of mirtazapine and fluoxetine in treatment of depression with generalized anxiety disorder in 35 patients eachChinese Journal of New Drugs and Clinical Remedy20042312853855
   Google Scholar
• WuFCLiHHuangXJClinical study of bupropion hydrochloride sustained-release tablets for GAD patientsGuide Of China Medicine20121021114116
   Google Scholar
• TuGHComparative study of Deanxit and fluoxetine in treatment of generalized anxiety disorderMedical Journal of Chinese People’s Health2010225554555
   Google Scholar
• ZhenHBDengHHZhangJPComparative study of buspirone and fluoxetine in treatment of generalized anxiety disorderChinese Journal of Neuropsychotic Disease1998244238239
   Google Scholar
• PollackMHKornsteinSGSpannMECrits-ChristophPRaskinJRussellJMEarly improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpointJ Psychiatr Res200842141176118418348888
   PubMed Web of Science ®Google Scholar
• MaJSYuJLOnce-weekly dosing of fluoxetine in the maintenance treatment of generalized anxiety disorderJ Clin Psychol Med20021228283
   Google Scholar
• BurkeWJMcArthur-MillerDAExploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorderJ Clin Psychiatry200162Suppl 22384211599647
   PubMed Web of Science ®Google Scholar
• EmmanuelNPWareMRBrawman-MintzerOBallengerJCLydiardRBOnce-weekly dosing of fluoxetine in the maintenance of remission in panic disorderJ Clin Psychiatry199960529930110362436
   PubMed Web of Science ®Google Scholar
• SchmidtMEFavaMRobinsonJMJudgeRThe efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorderJ Clin Psychiatry2000611185185711105738
   PubMed Web of Science ®Google Scholar
• WuZChenJYuanCDifference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION studyJ Affect Disord2013150383483923570952
   PubMed Web of Science ®Google Scholar
• SilverstonePHSalinasEEfficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorderJ Clin Psychiatry200162752352911488362
   PubMed Web of Science ®Google Scholar
• LiuZLWangLMLiuJXiaoSHEffect and safety of the treatment for comorbid anxiety and depression by use of short-term and low-dose olanzapine in combination with fluoxetineChinese Journal of Clinical Rehabilitation200593668
   Google Scholar